Skip to main content
OpenTrials
Completed

NCT Number: NCT04653415

Large Doses of Methylprednisolone Combined With Gabapentin in Total Knee Arthroplasty

The aim of the study was to assess whether administration of gabapentin and methylprednisolone as "pre-emptive analgesia" in a group of patients above 65 years of age would be effective in complex pain management therapy following total knee arthroplasty (TKA). For the study investigators will qualify one hundred seventy, above 65 years old patients. The participants will be double-blind randomized into two groups: the study and controls The study group will receive as "pre-emptive" analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone, while the others placebo. Perioperatively, all the patients will receive opioid and nonopioid analgesic agents calculated for 1 kg of body weight. Investigators will measure the levels of inflammatory markers (leukocytosis, C-reactive protein - CRP), pain intensity level at rest (numerical rating scale - NRS), the life parameters and all complications.

Completed

Looking for future studies?

Notify Me

Key information

About this study

The aim of the study was to assess whether administration of gabapentin and methylprednisolone as "pre-emptive analgesia" in a group of patients above 65 years of age would be effective in complex pain management therapy following total knee arthroplasty (TKA).170 patients operated on due to unilateral TKA will be double-blinded randomized into two groups: the study and the controls. Exclusion criteria are: clinical situation that 1/ restricted glucocorticoid administration: diabetes type 1 and 2, CRP levels above normal values (≥5 mg/l), chronic steroid treatment, peptic ulcers treated in the past 30 days and 2/and the chronic pain in the course of gonarthrosis, high intensity requiring use opioids.

The participants of the study will be subjected to the standardized procedure of subarachnoid anesthesia with subsequent unilateral femoral nerve block at the operated side, followed by the surgical procedure - unilateral TKA. The study group will receive as "pre-emptive" analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone, while the others placebo. Prior to anesthesia induction, the patients receive: anti-infection prophylactics intravenous cephazolin 2.0 g, for hemostasis control - tranexamic acid 1.0 g, an anti-emetic agent - ondansetron 8 mg. Fluid supply (crystalloids) will be standardized: 12 ml/kg in the first hour of surgery and 6 ml/kg in the following hours, packed red blood cells if blood loss exceeded 600 ml and hemoglobin concentration <10g/l during the time of operation. Pain management will be carried out based on the results of the NRS scales at rest. Every 6 hours NRS will be checked and intravenous PCA (patient-controlled analgesia) oxycodone hydrochloride, if pain was ≥4 points NRS or intravenous paracetamol, metamizole, if the pain was 2 - 4 NRS points will be administered, all pain medications will be calculated for 1 kg of body weight. In keeping with the ERAS (Enhanced Recovery After Surgery) protocol, on the day of surgery the patients will receive orally fluids and meals, will be mobilized and rehabilitated.

The study was approved by the institutional review board (nr 1072.6120.11.2020). Oral and written informed consent to participate in the study will be collected from all participants of the study. The statistical analysis of the groups will be performed to asess the demographic dates, life parameters, general condition in keeping with the ASA (American Society of Anesthesiology), POSSUM (Physiologic and Operative Severity Score for the enUmeration of Mortality and Morbidity) score, total dose of analgesic medications administered parenterally calculated for 1 kg of body mass in response to value of NRS at rest on day 0, time of administration the first dose, and duration of peripheral nerve block. On the day of surgery and on subsequent days, determinations will be made of glycemia levels and inflammatory markers: C-reactive protein (CRP) and leukocytosis levels.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients over 65 years old operated on unilateral total knee arthroplasty

Exclusion criteria

  • diabetes type 1 and 2,
  • CRP levels above normal values (≥5 mg/l),
  • chronic steroid treatment,
  • peptic ulcers treated in the past 30 days,
  • chronic pain in the course of gonarthrosis,

Treatment and study plan

Gabapentin 300mg

Drug

The study group will receive as "pre-emptive" analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone.

Methylprednisolone 125 mg

Drug

The study group will receive as "pre-emptive" analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone.

Tablet

Drug

The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - normal saline solution

Normal Saline 10 mL Injection

Drug

The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - normal saline solution

Primary outcomes

  1. Pain intensity assessed by NRS

    Time frame: change in every 6 hours on day 0

    The level of postoperative pain measured in the numerical rating scale (NRS) at rest (minimum 0 - no pain, maximum 10 - the maximum of pain).

  2. the dose of parenteral analgesics agents

    Time frame: 24 hours

    Dose of oxycodone hydrochloride in mg/kg body weight, paracetamol in mg/kg body weight, metamizole in g/kg body weight

  3. C-reactive protein (CRP) level

    Time frame: change in 0,1,2,3 days after surgery

    C-reactive protein (CRP) level measured in mg/l

  4. Leukocytosis level

    Time frame: change in 0,1,2,3 days after surgery

    Leukocytosis level measured in µL

  5. Adverse effects

    Time frame: 0 day after surgery

    The occurrence of adverse effects that would delay early rehabilitation, possible complication development, perioperative mortality to the POSSUM scale, comorbidities

  6. Adverse effects

    Time frame: 1 day after surgery

    The occurrence of adverse effects that would delay early rehabilitation, possible complication development, perioperative mortality to the POSSUM scale, comorbidities

  7. Adverse effects

    Time frame: 2 day after surgery

    The occurrence of adverse effects that would delay early rehabilitation, possible complication development, perioperative mortality to the POSSUM scale, comorbidities

  8. Adverse effects

    Time frame: 3 day after surgery

    The occurrence of adverse effects that would delay early rehabilitation, possible complication development, perioperative mortality to the POSSUM scale, comorbidities

  9. Adverse effects

    Time frame: 14 day after surgery

    The occurrence of adverse effects that would delay early rehabilitation, possible complication development, perioperative mortality to the POSSUM scale, comorbidities

Secondary outcomes

  1. Duration of femoral nerve blockade

    Time frame: on the day of surgery

    The time of femoral nerve block

  2. Blood glucose level

    Time frame: change in 0,1,2,3 days after surgery

    The level of glucose in blood in mmol/l

Other outcomes

  1. Mean age

    Time frame: the day of surgery

    Mean age in years

  2. Mean hospitalization time

    Time frame: from admission to hospital till 14 days after surgery

    Mean hospitalization time in days

  3. Mean postoperative hospitalization time

    Time frame: change from 0 till 14 days after surgery

    Mean postoperative hospitalization time in days

  4. Postoperative Mean Arterial Pressure (MAP)

    Time frame: change in 0,1,2,3 days after surgery

    Postoperative Mean Arterial Pressure (MAP) measured in mmHg

  5. Postoperative pulse

    Time frame: change in 0,1,2,3 days after surgery

    Postoperative pulse (x/min)) measured in x/min

  6. Postoperative saturation (Sp02) of the arterial blood

    Time frame: change in 0,1,2,3 days after surgery

    Postoperative saturation (Sp02) of the arterial blood measured in %

  7. Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM) morbidity

    Time frame: the day of the surgery

    Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM) morbidity measured in %

  8. Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM) mortality

    Time frame: the day of the surgery

    Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM) mortality measured in %

  9. Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM) physiological score

    Time frame: the day of the surgery

    Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM) physiological score measured in points (minimum 12, maximum 96)

  10. American Society of Anesthesiology Score (ASA)

    Time frame: the day of the surgery

    American Society of Anesthesiology Score (ASA), grade I-IV

Sponsors and collaborators

Lead sponsor

Jagiellonian University

Other

Registry information

Official study title

The Impact of Pre-emptive Large Doses of Methylprednisolone Combined With Gabapentin on Pain Treatment and Convalescence After Total Knee Arthroplasty in Elderly: A Double-blind Randomized Study

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Dec 4, 2020
Registry last updated
Dec 4, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.